GSK Executives Reinforce Commitment via Share Purchase
TipRanks (Fri, 19-Apr 11:57 AM ET)
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
Benzinga (Fri, 19-Apr 11:39 AM ET)
Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future
Benzinga (Thu, 18-Apr 12:06 PM ET)
GSK shingles vaccine shown 82% effective 11 years after vaccination
Seeking Alpha News (Wed, 17-Apr 1:26 PM ET)
GSK Executives Reinvest Dividends in Shares
TipRanks (Wed, 17-Apr 11:57 AM ET)
TipRanks (Wed, 17-Apr 10:40 AM ET)
GSK’s Shingrix Vaccine Proves Long-term Efficacy
TipRanks (Wed, 17-Apr 7:00 AM ET)
GSK’s New Antibiotic Shows High Success Rate
TipRanks (Wed, 17-Apr 7:00 AM ET)
GSK Corrects Executive Shareholding Disclosure
TipRanks (Tue, 16-Apr 10:27 AM ET)
GSK’s 5-in-1 Meningococcal Vaccine Under FDA Review
TipRanks (Tue, 16-Apr 6:57 AM ET)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) trades on the NYSE stock market under the symbol GSK.
As of April 19, 2024, GSK stock price climbed to $39.75 with 1,546,343 million shares trading.
GSK has a beta of 0.29, meaning it tends to be less sensitive to market movements. GSK has a correlation of 0.04 to the broad based SPY ETF.
GSK has a market cap of $81.21 billion. This is considered a Large Cap stock.
Last quarter GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) reported $10 billion in Revenue and $.72 earnings per share. This beat revenue expectation by $455 million and missed earnings estimates by -$.03.
In the last 3 years, GSK stock traded as high as $46.97 and as low as $28.47.
The top ETF exchange traded funds that GSK belongs to (by Net Assets): GCOW, PPH, AVDE, RODM, FENI.
GSK has underperformed the market in the last year with a return of +12.0%, while the SPY ETF gained +21.2%. In the last 3 month period, GSK fell short of the market, returning +1.6%, while SPY returned +4.3%. However, in the most recent 2 weeks GSK has outperformed the stock market by returning -2.7%, while SPY returned -3.5%.
GSK support price is $38.88 and resistance is $39.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GSK stock will trade within this expected range on the day.